Occurrence of Candidemia in Patients with COVID-19 Admitted to Five ICUs in France

• Main Authors: Berger, M. (Author), Blaize, M. (Author), Constantin, J.-M (Author), Demeret, S. (Author), Fekkar, A. (Author), Kamus, L. (Author), Kornblum, D. (Author), Lampros, A. (Author), Luyt, C.-E (Author), Mayaux, J. (Author), Monsel, A. (Author), Piarroux, R. (Author), Raoelina, A. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: Candida; candidemia; candidiasis; COVID-19; fungal infection; fungemia; SARS-CoV-2
• Online Access: View Fulltext in Publisher

 Whether severe COVID-19 is by itself a significant risk factor for the development of candidemia currently remains an open question as conflicting results have been published. We aim to assess the occurrence of candidemia in patients with severe COVID-19 admitted to the intensive care unit (ICU). We conducted a retrospective study on patients with severe SARS-CoV-2-related pneumonia admitted to 5 ICUs in France who were specifically screened for fungal complications between March 2020 and January 2021. The study population included a total of 264 patients; the median age was 56 years old and most of them were male (n = 186; 70.5%) and immunocompetent (n = 225; 87.5%), and 62.7% (n = 153/244) were on extracorporeal membrane oxygenation support. Microbiological analysis included 4864 blood culture samples and beta-glucan test performed on 975 sera. Candidemia was diagnosed in 13 (4.9%) patients. The species involved were mainly C. albicans (n = 6) and C. parapsilosis (n = 5). Almost all patients (12/13; 92.3%) had a colonization by yeasts. ICU mortality was not significantly impacted by the occurrence of candidemia. Unrelated positive beta-glucan tests were observed in 49 patients (23.4%), including 6 with mold infections and 43 with false positive results. In our series, patients with severe SARS-CoV-2-related pneumonia seemed at low risk of developing invasive candidiasis. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.